0001127602-24-009368.txt : 20240311 0001127602-24-009368.hdr.sgml : 20240311 20240311160832 ACCESSION NUMBER: 0001127602-24-009368 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240308 FILED AS OF DATE: 20240311 DATE AS OF CHANGE: 20240311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Deschatelets Pascal CENTRAL INDEX KEY: 0001657720 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 24738037 MAIL ADDRESS: STREET 1: 6400 WESTWIND WAY STREET 2: SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2024-03-08 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001657720 Deschatelets Pascal C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Scientific Officer 1 Common Stock 2024-03-08 4 M 0 69107 3.67 A 1185090 D Common Stock 2024-03-08 4 S 0 42750 61.8754 D 1142340 D Common Stock 2024-03-08 4 S 0 26257 62.6896 D 1116083 D Common Stock 2024-03-08 4 S 0 100 63.35 D 1115983 D Stock Option (Right to Buy) 3.76 2024-03-08 4 M 0 69107 0 D 2026-02-07 Common Stock 69107 106387 D This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023. This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023. This transaction was executed in multiple trades at prices ranging from $61.30 - $62.295. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023. This transaction was executed in multiple trades at prices ranging from $62.30 - $63.2925. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This is a scheduled exercise & sale from 10b5-1 trading plan dated 12/8/2023. This stock option was granted on 02/08/2016 and is fully vested. /s/ David Watson, attorney-in-fact for Pascal Deschatelets 2024-03-11